Phase II Results for Niraparib in Heavily Pretreated Patients With Ovarian Cancer
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses results from the phase II open-label, single-arm QUADRA study evaluating niraparib in patients with relapsed ovarian cancer who have received ≥3 prior chemotherapy regimens during the 2018 ASCO Annual Meeting.
During the 2018 ASCO Annual Meeting, Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses results from the phase II open-label, single-arm QUADRA study evaluating niraparib (Zejula) in patients with relapsed ovarian cancer who have received ≥3 prior chemotherapy regimens.
There was a 29% response rate found with niraparib, which is a very exciting result in this heavily pretreated population, Matulonis says. In patients with heavily pretreated ovarian cancer with a germlineBRCAmutation, the response rate was over 40%, while patients with platinum-resistant ovarian cancer had a response rate of approximately 25%.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
